Syndromic Management vs Point-of-Care, and Lab Based Testing for Chlamydia and Gonorrhoea: a Cost Comparison

By   |  | 

Despite higher costs per case tested, the WHO has recommended etiological testing in countries that can afford it as part of its 2016-2021 strategy for global STI control.3The added cost of etiological testing is possibly less than that of syndromic management if one considers the costs of caring for the many short- and long-term sequelae of untreated STIs, including ectopic pregnancy, pelvic inflammatory disease, and infertility in women, and additional complications for newborns. However, establishing this would require additional analysis.

Publication details